Thought Leadership Cell & Gene Drug Development

Developing CAR T for Solid Tumours: Interview with John Bridgeman, ImmunoKey

On-Demand
October 17, 2025
|
14:00 UK Time
|
Event lasts 11m
John Bridgeman

John Bridgeman

Chief Scientific Officer

ImmunoKey

Format: 11 Minute Interview

Related posts
Animal Free 3D Cell Culture and Organoid Growth: Interview with Aline Miller, University of Manchester

Animal Free 3D Cell Culture and Organoid Growth: Interview with Aline Miller, University of Manchester

Aline Miller University of Manchester
Cell & Gene
Nov, 2025
Developing CAR T for Solid Tumours: Interview with John Bridgeman, ImmunoKey

Developing CAR T for Solid Tumours: Interview with John Bridgeman, ImmunoKey

John Bridgeman ImmunoKey
Cell & Gene
Nov, 2025
Designing Next-Gen Biomaterials: Peptide Hydrogels in 3D Culture & Regenerative Platforms

Designing Next-Gen Biomaterials: Peptide Hydrogels in 3D Culture & Regenerative Platforms

Maryna Panamarova Wellcome Sanger Institute
Aline Miller University of Manchester
Vasiliki Kalodimou European University-Cyprus – Frankfurt Branch
Andy Wiranata Wijaya Nestlé
Cell & Gene
Nov, 2025
Commissioning ATMPs for the NHS: Interview with Sarah McAleer & Kiran Moyo, NHS England

Commissioning ATMPs for the NHS: Interview with Sarah McAleer & Kiran Moyo, NHS England

Sarah McAleer NHS England
Kiran Moyo NHS England
Cell & Gene
Nov, 2025
Centralised Off-The-Shelf Cell Therapies: Interview with Volker Huppert, Glycostem

Centralised Off-The-Shelf Cell Therapies: Interview with Volker Huppert, Glycostem

Volker Huppert Glycostem
Cell & Gene
Oct, 2025
Upcoming events
24
Mar
NextGen Biomed 2026

In-Person

NextGen Biomed has evolved over 18 years, from six individual events and communities into a unified platform designed to address the need for interdisciplinary collaboration, year-round engagement, and streamlined innovation and best practice sharing.

12
May
Computational Antibody Discovery

Online

Explore cutting-edge advancements in computational antibody discovery platforms, featuring real-world case studies on AI/ML in antibody engineering.

You're just a click away

To access our site, please accept the Terms of Use - our full terms of use are available below.
Full Terms of Use

By rejecting you won't be able to progress to the LifeScienceXchange platform.